Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Alisertib + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Alisertib||MLN8237||Aurka Inhibitors 24||Alisertib (MLN8237) binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation (PMID: 26999067, PMID: 32414750).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung small cell carcinoma||not applicable||Alisertib + Paclitaxel||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, Alisertib (MLN8237), alone and in combination with Taxol (paclitaxel), inhibited growth of small cell lung cancer cell (SCLC) lines in culture and inhibited tumor growth in primary human SCLC xenograft models (Mol Cancer Ther 2013;12(11 Suppl):A282).||detail...|
|Unknown unknown||lung small cell carcinoma||not applicable||Alisertib + Paclitaxel||Phase II||Actionable||In a Phase II trial, the combination treatment of Alisertib (MLN8237) and Taxol (paclitaxel) compared to Taxol (paclitaxel) plus placebo resulted in a progression-free survival of 3.32 months versus 2.17 months (P=0.038), and led to an overall response rate of 22% (20/89) versus 18% (16/289), and a disease control rate of 58% (52/89) versus 46% (41/89), respectively, in patients with relapsed or refractory small cell lung cancer (PMID: 31655296; NCT02038647).||31655296|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Alisertib + Paclitaxel||Preclinical - Pdx||Actionable||In a preclinical study, the combination of Alisertib (MLN8237) and Taxol (paclitaxel) worked synergistically or additively to inhibit tumor growth in cell line and patient-derived xenograft (PDX) models of triple-negative breast cancer (PMID: 24980948).||24980948|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02187991||Phase II||Paclitaxel Alisertib + Paclitaxel||Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer||Active, not recruiting||USA||0|